Business Context and Reporting Period
Company: Fresenius Medical Care AG & Co. KGaA (FMC)
Reporting Period: Three and nine months ended September 30, 2020
Overview: FMC is the world's largest kidney dialysis company, providing dialysis care, related services, and manufacturing health care products. The company operates through four geographic segments: North America, EMEA, Asia-Pacific, and Latin America. The reporting period was significantly influenced by the global COVID-19 pandemic, which necessitated operational changes, increased costs for protective measures, and resulted in the receipt of government relief funds, particularly under the U.S. CARES Act.
Key Financial Metrics
Revenue (Nine Months Ended Sept 30, 2020): €13,459 million (up 4% vs. prior year; up 6% at constant currency).
Operating Income: €1,843 million (up 11% vs. prior year).
Net Income Attributable to Shareholders: €987 million (up 15% vs. prior year).
Basic Earnings Per Share (EPS): €3.35 (up 19% vs. prior year).
Free Cash Flow: €2,913 million (up from €1,019 million in the prior year period), representing 21.6% of revenue.
Net Leverage Ratio: 2.8x (improved from 3.2x at December 31, 2019).
Cash and Cash Equivalents: €1,599 million as of September 30, 2020.
Debt and Lease Liabilities: €13,053 million.
Material Changes vs. Prior Period
- Revenue Growth: Driven by organic growth in health care services and products, partially offset by foreign currency translation effects. North America segment revenue increased 5% (constant currency), while EMEA and Asia-Pacific saw modest growth.
- Profitability: Operating income margin improved to 13.7% (from 12.8% in 2019), driven by higher gross profit margins and reduced selling, general, and administrative (SG&A) expenses as a percentage of revenue.
- Cash Flow: Net cash provided by operating activities surged to €3,649 million (from €1,796 million), largely due to U.S. federal relief funding, advanced Medicare payments, and improved working capital collections.
- Segment Performance:
- North America: Operating income increased 24% (constant currency) to €1,587 million, driven by the dialysis business and significant improvement in Care Coordination profitability.
- EMEA: Operating income decreased 16% (constant currency) to €278 million, impacted by a prior-year gain on contingent consideration and higher personnel expenses.
- Asia-Pacific: Operating income decreased 7% (constant currency) to €237 million, affected by unfavorable foreign currency transaction effects.
- COVID-19 Impact: The pandemic resulted in a net negative impact of €7 million to net income for the nine-month period, despite receiving approximately €253 million in U.S. federal relief funding and other reimbursements.
Guidance, Outlook, and Risks
Outlook and Commentary: Management expects to continue experiencing significant and unpredictable expenses and demand fluctuations related to COVID-19. The company anticipates capital expenditures of €1.1 to €1.3 billion for the full year 2020. No specific financial guidance for 2021 was provided in this filing, though management noted the uncertainty of the pandemic's duration and economic impact.
Key Risks and Contingencies:
- Regulatory and Reimbursement: Significant exposure to U.S. Medicare reimbursement rates (ESRD PPS) and potential changes to the Affordable Care Act (ACA). Ongoing investigations and litigation regarding billing practices, joint ventures, and compliance with the False Claims Act and Foreign Corrupt Practices Act (FCPA).
- Cybersecurity: In May 2020, the company's IT environment was attacked, resulting in the illegal publication of certain patient data. While no material financial impact was recorded, the risk of future attacks remains high.
- Internal Controls: The company disclosed a material weakness in internal control over financial reporting related to revenue recognition for fee-for-service arrangements under legal consideration. This weakness existed as of September 30, 2020, though management performed additional procedures to ensure the accuracy of the financial statements.
- Legal Proceedings: Various ongoing investigations by U.S. authorities (DOJ, SEC, USAO) regarding anti-bribery, billing practices, and joint ventures. A non-prosecution agreement with the DOJ and SEC was entered into in March 2019, with a compliance monitor in place.
Investor Verification Checklist
- Revenue Recognition Controls: Verify the status of remediation efforts for the disclosed material weakness regarding revenue recognition for fee-for-service arrangements under legal dispute.
- CARES Act Utilization: Confirm the extent to which received government relief funds have been offset against qualifying costs and the remaining liability recorded on the balance sheet.
- Reimbursement Rates: Monitor CMS proposed rules for the ESRD Prospective Payment System (PPS) for 2021 and potential impacts on the North America segment's margins.
- Legal Reserves: Review updates on ongoing litigation, particularly regarding the Granuflo/Naturalyte acid concentrate settlement and various False Claims Act investigations.
- Cybersecurity Posture: Assess the company's ongoing investment in IT security following the May 2020 data breach.